Active Ingredient History

  • Now
Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).   Wikipedia

  • SMILES: C1CN(CCO1)c2ccc(Nc3nc(cn4ccnc34)c5ccc6cn[nH]c6c5)cc2
  • Mol. Mass: 411.47
  • ALogP: 3.85
  • ChEMBL Molecule:
More Chemistry
6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine | entospletinib | gs-9973


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue